Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis.
S BanerjeeP GundaR F DrakeKamal A HamedPublished in: SpringerPlus (2016)
Use of LDT, as compared with other NUCs, is cost effective in CHB treatment in Chinese healthcare settings. Considering the detrimental renal impact, overall costs for all treatment options were increased. However, the increase for LDT was comparatively small.